The COQ5 Gene Encodes a Yeast Mitochondrial Protein Necessary for Ubiquinone Biosynthesis and the Assembly of the Respiratory Chain*

(Received for publication, November 21, 1996, and in revised form, January 14, 1997)

Elena Dibrov , Karen M. Robinson Dagger and Bernard D. Lemire §

From the The Medical Research Council of Canada Group in the Molecular Biology of Membranes, Department of Biochemistry, University of Alberta, Edmonton, Alberta T6G 2H7, Canada

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES


ABSTRACT

Saccharomyces cerevisiae is a facultative anaerobe capable of meeting its energy requirements by fermentation and is thus an ideal system for studying the biogenesis of respiring mitochondria. We have isolated a respiration-deficient mutant exhibiting a pleiotropic loss of the mitochondrial electron transport chain. The corresponding wild-type gene, COQ5, was cloned, sequenced, and able to restore respiratory growth. Deletion of the chromosomal COQ5 gene results in a respiration deficiency and reduced levels of respiratory protein components. Exogenously added decylubiquinone can partially restore electron transport chain function to mitochondrial membranes from the deletion mutant. The COQ5 nucleotide sequence predicts a polypeptide of 307 amino acids containing a mitochondrial targeting signal. COQ5p is 43% identical to the polypeptide predicted by the Escherichia coli open reading frame, o251 (1). The COQ5 gene, when introduced into E. coli, complements the respiratory deficiency of an ubiE mutant that maps near o251, suggesting that it is the yeast homolog of the ubiE gene product. We conclude that the COQ5 gene encodes the mitochondria-localized 2-hexaprenyl-6-methoxy-1,4-benzoquinone methyltransferase of the yeast ubiquinone biosynthetic pathway.


INTRODUCTION

The yeast, Saccharomyces cerevisiae, is the ideal organism for investigating the processes necessary for the production and maintenance of a functional electron transport chain in the mitochondria because it is able to make sufficient ATP for growth by fermentation. Respiration-deficient mutants form smaller colonies than wild-type cells when grown on glucose-containing media, and are therefore called petite. Such mutants can arise in two ways, by mutation of the nuclear genome giving rise to nuclear petites or by mutation of the mitochondrial genome giving rise to cytoplasmic petites. Thus, the biogenesis of the mitochondrial electron transport chain is a complex process involving the coordinate expression of both nuclear and mitochondrial genes.

Ubiquinone is a lipid component of the mitochondrial electron transport chain that serves to transport electrons from the NADH or succinate dehydrogenase complexes to the cytochrome bc1 complex, where it functions in a Q1 cycle to generate a proton motive force across the inner membrane (2). In addition to its mitochondrial location, ubiquinone is found in a variety of intracellular membranes and in lipoproteins, where it may serve as an antioxidant (3). Ubiquinone is also an electron carrier in the plasma membrane respiratory chains of prokaryotes.

In yeast, ubiquinone-deficient mutants have been assigned to eight complementation groups, coq1-coq8 (4). The proposed pathway for ubiquinone biosynthesis is derived from the accumulation of intermediates in mutant strains of Escherichia coli and S. cerevisiae (Fig. 5; Refs. 5-9). Yeast mutants in the COQ1, COQ2, COQ3, and COQ7 genes have been characterized (7, 8, 10, 11).


Fig. 5. The ubiquinone biosynthetic pathway. The proposed ubiquinone biosynthetic pathways of eukaryotes and prokaryotes is thought to diverge after the synthesis of intermediate I. The length of the isoprenoid chain (R) varies depending on the species; in yeast it is 6 units long, and in E. coli it is 8 units long. The intermediates are as follows: I, 3-polyprenyl-4-hydroxybenzoate; II, 2-polyprenylphenol; III, 2-polyprenyl-6-hydroxyphenol; IV, 3,4-dihydroxy-5-polyprenylbenzoate; V, 3-methoxy-4-hydroxy-5-polyprenylbenzoate; VI, 2-polyprenyl-6-methoxyphenol; VII, 2-polyprenyl-6-methoxy-1,4-benzoquinone; VIII, 2-polyprenyl-3-methyl-6-methoxy-1,4-benzoquinone; IX, 2-polyprenyl-3-methyl-5-hydroxy-6-methoxy-1,4-benzoquinone; X, ubiqinone. Relevant E. coli and yeast mutations are listed above and below the affected biosynthetic reactions, respectively. This figure is modified from one presented by Marbois and Clarke (8).
[View Larger Version of this Image (14K GIF file)]


We have been interested in the biogenesis of the succinate dehydrogenase complex of the electron transport chain and the tricarboxylic acid. This enzyme is composed of four nuclear encoded protein products, a covalent FAD cofactor, iron-sulfur clusters, and heme and donates the electrons derived from succinate to ubiquinone (12). To better understand the biogenesis of this enzyme, we have isolated nuclear petite mutants that are defective in succinate dehydrogenase. Mutations affecting the biogenesis of more than one enzyme will have pleiotropic effects on mitochondrial function. A large number of pleiotropic mutants have been isolated, but few have been studied (4). We have studied one such mutant, TCM7, that has lost several respiratory chain activities including succinate oxidase activity.

The TCM7 mutant was complemented to respiration proficiency by transformation with a genomic yeast DNA library. The complementing gene, identified as COQ5, has been cloned, and its nucleotide sequence has been determined. It corresponds to a hypothetical protein encoded on chromosome XIII, YM8339.09c, whose sequence is retrievable under the GenBankTM accession number P49017[GenBank]. COQ5 encodes a protein of 34.7 kDa (307 amino acids), which has an amino terminus that resembles a mitochondrial targeting sequence. The COQ5 gene probably encodes a methyltransferase in the ubiquinone biosynthetic pathway, since its expression in E. coli can complement a ubiE mutant, which lacks the 2-octaprenyl-6-methoxy-1,4-benzoquinone methyltransferase. Furthermore, the succinate oxidase activities of cytoplasmic membranes from an E. coli ubiE mutant or of yeast mitochondrial membranes from a coq5 mutant can be partially restored in vitro by the addition of quinone analogs.


EXPERIMENTAL PROCEDURES

Strains and Media

The yeast strains used in this study are listed in Table I. Yeast media have been described (13, 14). Yeast transformation was with lithium acetate (15). The E. coli strain, AN70 (Hfr, metB, StrR,ubiE-401), was kindly provided by Dr. Ian G. Young (16).

Table I.

Saccharomyces cerevisiae strains


Strain Genotype Parent/Source

MH125 a trp1 ura3-52 leu2-3,112 his 3 his 4 rme Laboratory collection
MH123 a/alpha trp1 ura3-S2 leu2-3,112 his 3 his 4 rme Laboratory collection
DAUL1 alpha ade2 ura3 Delta  lys2 Laboratory collection
TCM7 MH125, coq5-1 This work
TCM7-2A5A alpha his ade2 lys2 ura3 LEU2 TRP1 coq5-1 TCM7 and DAUL1
ED7 MH125, coq5Delta -1::TRP1 This work
CH83-B1 alpha ade2-1 his3-11 leu2-3,112 trp1-1 ura3-1 coq5 Dr. C. Clarke
CH83-B3 alpha ade2-1 his3-11 ura3-1 coq5 Dr. C. Clarke
a4rho0 a ade1 lys2 [rho0] Laboratory collection
MS10  alpha kar1-1 leu2-3 canR [rho0] Laboratory collection

Mutant Isolation

MH125 was grown to stationary phase in YPD (1% yeast extract, 2% peptone, 2% dextrose), diluted 10-fold in water, and irradiated with ultraviolet light at 254 nm (1.4 J/m2 s) for 9 min to achieve about 95% killing. petite strains that stained red with 2,3,5-triphenyltetrazolium chloride and secreted acid were identified as described and were candidate succinate dehydrogenase mutants (14). Mitochondrial membranes were isolated and assayed for the NADH- and the succinate-dependent reduction of cytochrome c as described (13), and strains, such as TCM7, displaying an apparently selective loss of the succinate-dependent activity were further analyzed.

Cloning and Identification of the COQ5 Gene

The mutant, TCM7, was transformed with a yeast genomic DNA library (17) and transformants were selected for uracil prototrophy on SD (0.67% yeast nitrogen base without amino acids, 2% dextrose plates. Approximately 6,000 transformants were replica-plated to SG (0.67% yeast nitrogen base without amino acids, 3% glycerol) plates to test for complementation to respiration proficiency. The plasmids were recovered and analyzed by restriction mapping; this resulted in the isolation of two complementing plasmids with overlapping inserts. A 3.0-kb restriction fragment from a partial Sau3AI digest was cloned into the vector, YCplac33 (18), to give the complementing plasmid, p7S6. Exonuclease digestions and the production of nested deletions were performed as described by the supplier (Stratagene, La Jolla, CA). All deletions affecting the COQ5 open reading frame resulted in the loss of complementation. The COQ5 gene sequence was obtained for both strands using an Applied Biosystems 373A DNA sequencer.

Construction of a Chromosomal Disruption Mutant

The plasmid, pSK7-TRP (described in the legend to Fig. 1), was linearized and used to transform MH125 and MH123 to tryptophan prototrophy by selection on SD medium supplemented with histidine, uracil, and leucine. At least 30 stably transformed, MH125-derived tryptophan prototrophs had also lost the ability to grow on YPG (1% yeast extract, 2% peptone, 3% glycerol), and 4 were further examined. Polymerase chain reactions (19) with the oligonucleotides 5'-TGGAAACTAGCTTCCGCATT-3' and 5'-CTAACAGTAATCTCGCAGTT-3' were used to amplify the COQ5 region and verify the presence of the disruption allele, coq5Delta -1::TRP1, in the transformants.


Fig. 1. Construction of a chromosomal deletion mutant. The 3-kb Sau3AI fragment from the plasmid p7S6 that encodes the COQ5 gene was transferred to the vector pBluescript II SK+ as a HindIII to SstI fragment. The 1.11-kb MunI to EcoRI fragment carrying the entire COQ5 gene was replaced with a 0.85-kb EcoRI fragment encoding the selectable marker, TRP1, creating the plasmid pSK7-TRP. The TRP1 and the COQ5 open reading frames are represented as boxes, while flanking DNA is represented as lines.
[View Larger Version of this Image (10K GIF file)]


Construction and Expression of a Tagged COQ5 Protein

A polymerase chain reaction with the following oligonucleotides 5'-CATAGATTGTGGAAGGACCA-3' and 5'-CTTCGTCGACTTACAAGTCTTCTTCAGAAATAAGCTTTTGTTCACCTCCAACTTTAATGCCCCAATGG-3' was performed to add the 10-residue c-myc protooncogene sequence recognized by the monoclonal antibody, 9E10, to the carboxyl terminus of COQ5p (20). The latter oligonucleotide also incorporates two glycine residues between the COQ5 and the c-myc sequences, a stop codon, and a SalI restriction site for cloning. The carboxyl-terminal 280 base pairs of COQ5, now tagged with the myc sequence were amplified, digested with XbaI and SalI, and cloned into likewise digested p7S6 to generate p7S6myc encoding the tagged protein. The amplified region was sequenced to confirm the construction. For overexpression of the tagged COQ5p, the 1.0-kb MunI to SalI fragment encoding the entire gene was cloned into the vector, pUCu, under control of the copper-inducible CUP1 promoter (20) to generate pUCu-7myc. This plasmid was introduced into MH125, the transformants were grown on lactate medium (21) and inoculated into lactate medium supplemented with 20 µg/ml histidine, leucine, and tryptophan containing 0.5 mM CuSO4. Samples for Western blot analysis were prepared and transferred to nitrocellulose as described (13) and detected with the monoclonal antibody, 9E10 (Chemicon International, Inc., Temecula, CA), goat anti-mouse secondary antibody (Bio-Rad Laboratories Ltd., Hercules, CA), and the ECL detection system (Amersham Canada Ltd., Oakville, Ontario, Canada).

Mitochondrial Protein Import

The 1.0-kb MunI to SalI fragment from p7S6myc was cloned into pBluescript II KS- under the control of the T7 promoter. Template mRNA was produced by in vitro transcription using T7 RNA polymerase (Life Technologies Inc., Burlington, Ontario, Canada) and translated in rabbit reticulocyte lysate as described by the supplier (Promega Corp., Madison, WI) using Tran35S-Label (ICN Biomedicals, St. Laurent, Quebec). Import reactions were performed as described (22).

Miscellaneous Methods

Standard procedures were used for plasmid isolation from E. coli (23). Yeast mitochondrial membranes and enzymatic activities were measured as described (13). Everted bacterial vesicles were prepared (24), and respiratory activities were measured in a Clark-type electrode (Rank Brothers, Cambridge, UK). The ubiquinone analogs, decylubiquinone (Q0), and 2,3-dimethoxy-5-methyl-1,4-benzoquinone (Q2) (Sigma) were added as ethanolic solutions. Immunofluorescence localization of COQ5p was performed as described (25) using fluorescein isothiocyanate-coupled goat anti-mouse as secondary antibody (Chemicon). Ubiquinone and its intermediates were isolated from E. coli by extraction with ethanol/ethyl ether (3:1) as described (26).


RESULTS

TCM7 Is a Nuclear petite Mutant

To better understand the mechanisms by which complex membrane proteins are assembled into the mitochondrial inner membrane, we have screened for mutants that are defective in the activity of our model protein, succinate dehydrogenase. Succinate dehydrogenase mutants are unable to grow on glycerol as a sole carbon source but still possess a functional electron transport chain linking NADH or glycerol-1-phosphate oxidation to the reduction of oxygen (13, 27). In our screen, we took advantage of the observation that strains unable to grow on glycerol form small or petite colonies on YPDG (1% yeast extract, 2% peptone, 0.1% dextrose, 3% glycerol) plates (28). rho 0 or rho - strains that are completely lacking an electron transport chain due to defects in their mitochondrial genomes were identified by their inability to reduce tetrazolium dye and eliminated. The secretion of acid, as monitored by the indicator dye, bromcresol purple, is taken as an indication of tricarboxylic acid cycle mutants (14). Tetrazolium staining, acid-secreting petites were grown on liquid YPD-0.6% (1% yeast extract, 1% peptone, 0.6% glucose, 0.1% KH2PO4, 0.12% (NH4)2SO4, pH 6.2), harvested, and lysed in a French pressure cell to isolate submitochondrial membranes (13). Succinate- and NADH-cytochrome c reductase activities were measured; loss of the former and retention of the latter activity was taken as a preliminary indication of a succinate dehydrogenase mutant. In MH125, a substantial amount of antimycin A-insensitive NADH-cytochrome c reductase activity was induced, a phenomenon that has been reported previously (29, 30). This resulted in the isolation of putative succinate dehydrogenase mutants, which upon closer examination were revealed to have pleiotropic losses of mitochondrial respiratory functions. The mutant, TCM7, is thus a nuclear petite with a pleiotropic loss of most respiratory chain proteins, including the cytochrome bc1 complex and succinate dehydrogenase. It defines one of four complementation groups isolated. When the mutant is mated and the resulting diploid is sporulated, the respiration deficiency in TCM7 segregates 2:2 in over 20 tetrads as expected of a single-gene, nuclear mutation.

Construction of a TCM7 Null Allele

To more fully characterize the function of the TCM7 gene in a nonmutagenized background, we decided to clone the wild-type gene (see "Experimental Procedures") and to create a null allele by a one-step gene disruption (Fig. 1). The plasmid, pSK7-TRP, was transformed into the haploid, MH125, and the diploid, MH123, and tryptophan prototrophs were selected. Verification of the presence of the tcm7Delta -1::TRP1 allele in both haploid and diploid transformants was shown by polymerase chain reactions using genomic DNA as template (Fig. 2, lanes 2 and 4, respectively). The successful isolation of disruption mutants in the haploid, MH125, indicates that TCM7 is not essential for viability (lane 4). The disruption mutant, ED7, like TCM7, is respiration-deficient; it does not grow on YPG and has a low growth yield on a medium containing low levels of glucose (not shown). When mated to the tcm7-1 mutant, TCM7-2A5A, ED7 was not complemented, indicating the tcm7Delta -1::TRP1 allele belongs to the same complementation group as the tcm7-1 mutation in TCM7-2A5A and TCM7. ED7 is also rescued to respiration proficiency by the plasmid, p7S6. When a diploid carrying a single copy of the tcm7Delta -1::TRP1 disruption is sporulated, respiration deficiency and tryptophan prototrophy cosegregated in six dissected tetrads.


Fig. 2. Genomic structure of the chromosomal disruption mutants. Whole cells of tryptophan prototrophic, respiration-deficient transformants of the yeast strains, MH123 (diploid) and MH125 (haploid), were assessed for the presence of the disruption allele by a polymerase chain reaction using approximately 107 cells/reaction (19). Reaction conditions were 5 min at 99 °C, followed by 30 cycles of 30 s at 94 °C, 30 s at 56 °C, and 90 s at 72 °C followed by 5 min at 72 °C. Size markers (lane M) and the products of reactions with 0.1 µg of the plasmid, pSK7-TRP (lane 1), an MH123 transformant (lane 2), MH123 (lane 3), and the MH125 transformant named ED7 (lane 4) were resolved by agarose gel electrophoresis. The positions of size markers in kilobases are indicated on the left. The positions of the expected products for the COQ5 (1.4-kb) and the coq5Delta -1::TRP1 (1.1-kb) alleles are indicated on the right.
[View Larger Version of this Image (22K GIF file)]


TCM7 Is a coq5 Mutant

As discussed below, we discovered that the cloned TCM7 gene could complement an E. coli ubiquinone biosynthetic mutant. This raised the possibility that the TCM7 gene encodes an enzyme of the yeast ubiquinone biosynthetic pathway. When TCM7 or ED7 are mated to the known coq5 mutant, CH83-B3, the diploids remain respiration-deficient, demonstrating that the mutations are allelic. As a control, we ensured that all haploids were rho + by mating them to the rho 0 tester strains and verifying the respiration competency of these diploids. Furthermore, we could complement the coq5 mutants, CH83-B1 and CH83-B3, with the plasmid p7S6. From these data, we conclude that TCM7 and ED7 are coq5 mutants, and we refer to the TCM7 gene as COQ5. We could not restore respiratory growth to TCM7 or ED7 by supplementing the medium with coenzyme Q2, but this property is not universal to ubiquinone biosynthetic mutants (31).

COQ5 Encodes a Mitochondrial Protein

The nucleotide sequence of the COQ5 gene was determined and is identical to part of the sequence found in GenBankTM (accession number Z49210[GenBank]). The predicted protein sequence suggests that COQ5p is synthesized as a precursor protein that is imported into and cleaved by mitochondria, since the amino-terminal 31 amino acids are rich in basic and hydroxylated residues and devoid of acidic ones. To investigate the localization of COQ5p, we constructed a fusion protein containing the entire COQ5p, two glycine residues as a spacer domain, and the 10-residue c-myc sequence that serves as an antibody recognition site. The myc-tagged COQ5 produced a functional protein, since it could complement the mutants, TCM7 and ED7. When the fusion protein was expressed under the control of the inducible CUP1 promoter and the cells were fractionated, it was primarily detected in the mitochondrial fraction by Western blot analysis (Fig. 3A, lane 3). Ready detection of the tagged COQ5p could be seen when expression was under the control of the uninduced CUP1 promoter but not when expression was mediated by the COQ5 promoter (not shown). This suggests that COQ5p is not normally a highly expressed protein. Immunofluorescence analysis of cells overexpressing the myc-tagged COQ5p produced a punctate staining pattern characteristic of mitochondrial proteins (not shown). When mitochondria were further fractionated, COQ5p was predominantly found in the matrix fraction (Fig. 3B, lane 2 of c-myc panel). Small amounts were also found associated with the membrane fractions (lane 1) or the intermembrane space (lane 3), but these levels reflect cross-contamination of fractions as judged by the membrane (porin), matrix (hsp60), and intermembrane space (cytochrome b2) marker proteins. Our mitochondrial fractions contain contaminating organelles that co-purify, and hence we cannot exclude the possibility that COQ5p is located in other organelles beside mitochondria.


Fig. 3. COQ5p is a mitochondrial protein. Samples of mitochondrial proteins from lactate-grown cells, MH125 (lanes 2, 4, and 6) and MH125, with the plasmid pUCu-7myc (lanes 1, 3, and 5) were run on a 10% acrylamide gel and transferred to a nitrocellulose membrane for Western blot analysis with anti-myc antibodies. A, lanes 1 and 2, 100 µg of cytosolic fractions; lanes 3 and 4, 100 µg of mitochondrial fractions; lanes 5 and 6, 100 µg of cell homogenates. The position of the myc-tagged COQ5p protein is indicated by the arrow. The positions of size markers in kilodaltons are indicated on the left. B, 400 µg of mitochondria from MH125 carrying the plasmid pUCu-7myc were fractionated into membrane (lane 1), matrix (lane 2), and intermembrane space (lane 3) fractions as described except that 2 M urea was included in the mitoplast resuspension buffer (40). Identical samples of 10% of each fraction were resolved on 12% acrylamide gels, transferred to nitrocellulose, and probed with anti-myc, anti-heat shock protein 60 (hsp60), anti-porin, and anti-cytochrome b2 antibodies. All antibodies were diluted 10,000-fold.
[View Larger Version of this Image (33K GIF file)]


To independently confirm that COQ5p is a mitochondrial protein, in vitro synthesized precursor protein was imported into isolated yeast mitochondria (Fig. 4). COQ5p bound to mitochondria (lanes 2 and 4) and could be imported in an energy-dependent manner (lanes 4 and 5) to a protease-protected location (lane 3) that is made accessible by the addition of detergent (lane 6). Import is accompanied by a proteolytic cleavage event to a faster migrating species (lanes 2 and 3). The COQ5p presequence contains the sequence RCdown-arrow FTQAHRACdown-arrow which resembles the consensus sequence for twice cleaved precursor proteins, RXdown-arrow (F/L/I)XX(T/S/G)XXXXdown-arrow (32). This motif is found in many proteins required for respiratory function (32) and would predict that lysine 31 is the mature amino terminus. We have not detected the presence of an intermediate species in the maturation of COQ5p in our experiments.


Fig. 4. In vitro import of COQ5p. myc-tagged COQ5p was produced by in vitro transcription and translation in rabbit reticulocyte lysate. Import reactions were performed with 150 µg of mitochondria in the presence of 10 mM succinate and 2 mM NADH for 30 min at 30 °C (40). The mitochondria were reisolated and analyzed by denaturing gel electrophoresis and fluorography (40). Lane 1, 10% of the amount of lysate added to each import reaction; lane 2, mitochondria that have imported the COQ5p precursor; lane 3, same as lane 2 but after treatment with 250 µg of proteinase K/ml; lane 4, same as lane 2 but in the presence of 10 µM valinomycin; lane 5, same as lane 3 but in the presence of 10 µM valinomycin; lane 6, mitochondria incubated with COQ5p precursor, reisolated, disrupted by the addition of 1% Triton X-100, and treated with proteinase. The positions of size markers in kilobases is indicated on the right. p, precursor form; m, mature form.
[View Larger Version of this Image (15K GIF file)]


The Yeast COQ5 Complements an E. coli ubiE Mutant

The sequence of COQ5p is 42.8% identical to the polypeptide encoded by o251, an open reading frame located at 86 min on the E. coli chromosome (1). Interestingly, three mutations that lead to respiration deficiency in E. coli had also been mapped to this region but not assigned to any open reading frame; these are ubiB, ubiD, and ubiE (33). These mutations lead to defects in ubiquinone biosynthesis that are manifested as an inability to grow on the nonfermentable carbon source, succinate. The ubiB and ubiD gene products are part of a prokaryotic specific ubiquinone biosynthetic pathway and are believed to catalyze the conversion of intermediates II to III and I to II, respectively (Fig. 5). The ubiE gene product was proposed to catalyze a reaction common to the eukaryotic and the prokaryotic pathways, the methylation of intermediate VII to intermediate VIII, because an ubiE mutant accumulates 2-octaprenyl-6-methoxy-1,4-benzoquinone (intermediate VII; Ref. 5). To determine whether the COQ5p could be the yeast homolog of the ubiE gene product, we transformed a ubiE mutant, AN70, with the plasmid p7S6. COQ5 is able to complement AN70 and restore growth on succinate. Furthermore, when the quinone pools are extracted from AN70, quinones are not detectable by thin layer chromatography in either chloroform/benzene (1:1) or in chloroform/methanol (95:5) solvent systems (not shown). In contrast, the quinone pool from AN70 expressing COQ5 contained compounds that comigrate with a Q0 standard in both solvent systems used (RF (relative mobilities) = 0.2 and 0.85, respectively). This result suggests strongly that COQ5 complements AN70 by restoring ubiquinone biosynthesis.

Membrane vesicles prepared from AN70 have no detectable succinate oxidase activity (Fig. 6). The addition of increasing concentrations of Q0 restored succinate oxidase activity. Membrane vesicles from AN70 transformed with p7S6 displayed a high level of succinate oxidase activity in the absence of added quinone; this level of oxidase activity is similar to that found in a related wild-type strain of E. coli (34). The addition of 200 µM coenzyme Q0 to COQ5-complemented bacterial membranes only slightly increased respiratory activity, indicating that the yeast COQ5p had restored adequate quinone levels.


Fig. 6. Succinate oxidase activities can be stimulated by added quinone. AN70 (solid bars) or AN70 with the plasmid, p7S6 (hatched bars), was grown on Luria Broth with 20 mM glucose and harvested, and everted membrane vesicles prepared as described (24). To a 1.5-ml chamber filled with buffer (50 mM Tricine, pH 7.5, 10 mM MgSO4, 150 mM KCl) was added 3 mg of bacterial membrane protein. Oxidase measurements were begun with the addition of the desired amount of Q0 followed by the addition of 10 mM sodium succinate, pH 7.4.
[View Larger Version of this Image (38K GIF file)]


Exogenous Quinone Stimulates Respiration in ED7 Mitochondrial Membranes

Submitochondrial membranes were prepared from the yeast disruption mutant, ED7, and its wild-type parent, MH125, and analyzed for respiratory chain activities (Table II). ED7 membranes showed a dramatic loss of NADH oxidase and NADH-cytochrome c reductase activities. Even more dramatically, succinate oxidase and succinate-cytochrome c reductase activities were undetectable, although a small amount of succinate-dependent phenazine methosulfate-mediated reduction of the artificial electron acceptor, dichlorophenol indophenol, a ubiquinone-independent activity, remained. The addition of 200 µM decylubiquinone, Q2, led to the severalfold stimulation of some of the respiratory activities, with NADH oxidase activity being most affected. Higher concentrations of quinone could not further increase activity levels. The ED7 culture used in this experiment had remained at least 75% rho +; the less than full recovery of respiratory chain activities with added quinone cannot be accounted for by mitochondrial DNA mutations.

Table II.

Respiratory chain activities of mitochondrial membranes


Activity MH125 ED7 ED7 with 200 µM Q2

Succinate oxidasea 59 NDb ND
NADH oxidasea 241 5 14
Succinate-cytochrome c reductasec 29 ND 1
NADH-cytochrome c reductasec 315 13 27
Succinate-dichlorophenol indophenol reductased 172 4  ---e

a Activities are expressed as nanoatoms of oxygen min-1 mg-1.
b ND, not detectable.
c Activities are expressed as nmol of cytochrome c reduced min-1 mg-1.
d Activities are expressed as nmol of dichlorophenol indophenol reduced min-1 mg-1.
e Not done.

The COQ5 Mutant Has Lowered Levels of Electron Transport Chain Components

The failure of added quinone to fully restore respiratory function to ED7 mitochondrial membranes might be due to lower levels of assembled respiratory chain components. We examined mitochondrial membranes for the presence of respiratory chain components by Western blot analysis and normalized mutant and wild-type samples by loading equivalent amounts of the outer membrane protein, porin (Fig. 7A). We reasoned that respiratory deficiency should not affect the import of mitochondrial outer membrane proteins, since their insertion is energy-independent (35). We detected low levels (less than 10%) of succinate dehydrogenase with an antibody against the iron-sulfur subunit (panel B), low levels of ATP synthase with antibodies against the beta -subunit (panel C), and low levels of cytochrome c oxidase with antibodies against subunit IV (panel D), consistent with the reduced enzymatic activities reported in Table II. Therefore, a ubiquinone deficiency as present in the COQ5 null mutant leads to lowered steady state levels of electron transport chain components.


Fig. 7. COQ5p mitochondria contain decreased levels of respiratory chain components. Mitochondrial samples of ED7 (lane 1) or ED7 carrying the plasmid, p7S6myc (lane 2) were resolved on 10% acrylamide gels, transferred to nitrocellulose, and probed with anti-porin (A), anti-SDH2p (B), anti-ATP synthase beta -subunit (C), and anti-cytochrome c oxidase subunit IV (D) antibodies. All antibodies were diluted 10,000-fold. The positions of the relevant proteins are indicated by the arrows. The positions of size markers in kilodaltons are indicated on the left.
[View Larger Version of this Image (14K GIF file)]



DISCUSSION

In this study, we characterize a coq5 mutant, isolate the corresponding wild-type COQ5 gene, and provide evidence that COQ5p is involved in ubiquinone biosynthesis in S. cerevisiae. Loss of COQ5 function and the resultant loss of ubiquinone synthesis should result in a respiration-deficient phenotype that is manifested as an inability to grow on nonfermentable carbon sources. The original mutant, TCM7, however, is at least partially respiration-proficient in that it is able to reduce the tetrazolium dye used in our mutant screen, suggesting that the coq5-1 allele is leaky. Mutations that completely block ubiquinone biosynthesis might not have been detected by our screening procedure. The secretion of acid by TCM7 and the low succinate dehydrogenase activity in the COQ5 disruption mutant (Table II) suggest that the tricarboxylic acid cycle is also impaired. We have not measured the levels of other tricarboxylic acid cycle enzymes.

The E. coli ubiE mutant, AN70, is characterized by an inability to grow on nonfermentable carbon sources such as succinate and by low oxidase activities (33). Expression of the yeast COQ5 gene restores the bacterium's ability to grow with succinate as the carbon source and the succinate oxidase activity of isolated bacterial membranes. The COQ5 gene also rescues the ubiquinone synthesis deficiency of the ubiE mutation; although we did not characterize the exact nature of the products, the COQ5 gene results in the production of quinone compounds with a mobility by thin layer chromatography similar to Q0 in a chloroform/methanol solvent system.

The ubiE mutant accumulates intermediate VII or 2-octaprenyl-6-methoxy-1,4-benzoquinone (Fig. 5; Ref. 16). Restoration of ubiquinone biosynthesis in AN70 by the yeast COQ5 strongly suggests that COQ5p is the methyltransferase that modifies position 3 of the benzoquinone ring. We have not attempted to show methyltransferase activity in vitro nor have we attempted to isolate the intermediates that accumulate in ED7. There are two other methyltransferases, both O-methyltransferases, in the ubiquinone biosynthetic pathway. The yeast COQ3 gene encodes the 3,4-dihydroxy-5-hexaprenylbenzoate methyltransferase, which converts intermediate IV to V. It has been cloned, sequenced, and characterized and is distinct from the COQ5 gene (7). The second O-methyltransferase catalyzes the final step in the pathway, converting intermediate IX to ubiquinone (X) and has not been characterized in yeast (9). In E. coli, the second O-methyltransferase is encoded by the E. coli ubiG gene. The ubiG gene has recently been shown to complement a yeast coq3 mutant, strongly suggesting that the ubiG protein catalyzes both O-methyltransferase reactions in E. coli and leading to speculation that a bifunctional O-methyltransferase may also exist in yeast (9). The ubiG gene has been sequenced and is not related in sequence to the yeast COQ5 gene except in the proposed S-adenosylmethionine binding domains (Fig. 8; Ref. 6). The simplest explanation for our results is that COQ5 encodes the yeast 2-hexaprenyl-6-methoxy-1,4-benzoquinone methyltransferase, which can functionally complement a mutation in the E. coli homolog encoded by the ubiE gene.


Fig. 8. Alignments of methyltransferase sequences. A, alignment of region I sequences (36) for COQ5p (this work), human glycine methyltransferase (Gly MT) (GenBankTM accession number X62250[GenBank]), yeast 3,4-dihydroxy-5-hexaprenylbenzoate methyltransferase (DHHB MT) (7), E. coli 2-octaprenyl-3-methyl-5-hydroxy-6-methoxy-1,4-benzoquinone methyltransferase (UbiGp) (6). B, alignment of region III sequences (36) for COQ5p, glycine methyltransferase, human D-aspartyl/L-aspartyl protein methyltransferase (36) (Asp MT), and UbiGp. The numbers to the right of the sequence names indicate amino acid residue numbers in each protein. The boxed residues are identical to the COQ5p sequence. h, hydrophobic residue; D/E, either aspartic or glutamic acid; x, any residue; c, a charged residue.
[View Larger Version of this Image (21K GIF file)]


The COQ5p sequence is weakly related to other methyltransferases; it does contain a closely related version of a consensus amino acid sequence common to methyltransferase enzymes that use S-adenosylmethionine as a donor (Fig. 8; Refs. 6 and 36). As in the human glycine methyltransferase sequence, the first of the conserved glycines in the motif is replaced by an alanine in COQ5p, but the remainder of the adjacent COQ5p sequence conforms to the consensus motif (Fig. 8A). There is a second region of sequence similarity found in a smaller number of methyltransferases that is also found in COQ5p (Fig. 8B; Ref. 36). These sequence similarities are consistent with the use of S-adenosylmethionine as the donor for all the methyl groups in the ubiquinone biosynthetic pathway (37).

We localized COQ5p to the mitochondrial matrix by Western blot analysis of a tagged, overexpressed protein (Fig. 3) and by in vitro import into isolated mitochondria (Fig. 4). This localization is consistent with the proposed role for Coq5p in ubiquinone biosynthesis, which is generally believed to be compartmentalized within mitochondria (7). Complementation of a yeast coq3 mutant by the E. coli ubiG gene required the addition of a mitochondrial targeting signal to the ubiG gene, indicating a need for organellar targeting of some proteins in the ubiquinone biosynthetic pathway (9). The predicted protein sequence does not contain any putative membrane-spanning domains, so COQ5p was expected to be soluble. In E. coli, the enzymes of the ubiquinol biosynthetic pathway that can convert 2-octaprenylphenol (intermediate II) to ubiquinone-8 can be released from membranes as a complex without detergent despite the hydrophobic nature of their substrates (37). Ubiquinone's primary role is in electron transfer to the cytochrome c reductase complex in the mitochondrial respiratory chain, consistent with a mitochondrial site of synthesis, but it is also found in other eukaryotic organelles where its function is less well defined.

The addition of an ubiquinone analog to ED7 ubiquinone-deficient membranes only partially restores respiratory activities, particularly succinate oxidase activity. In contrast, the ubiE mutant, AN70, which is similarly blocked in ubiquinone synthesis, shows a more marked recovery of succinate oxidase activity with added Q0 (Fig. 6). We have shown that the partial recovery of respiratory activities is likely attributable to the substantially lower levels of respiratory chain components in ED7 membranes (Fig. 7 and Table II). Why does the absence of COQ5p lead to low levels of respiratory chain components in yeast, whereas some other nuclear petite mutations do not? For example, sdh1 or sdh4 mutants have normal levels of NADH oxidase activities in their mitochondrial membranes, despite their respiration deficiencies due to losses of succinate dehydrogenase subunits (13, 27). A yeast coq3 mutant also has normal levels of succinate or NADH oxidase activities if a quinone analog is added to the assays (30).

We do not believe ubiquinone deficiency is affecting the translocation of proteins into the organelle. Even cytoplasmic petite mutants that are devoid of respiratory activity are still able to import and assemble normal F1-ATP synthase (38). One possibility is that a lack of ubiquinone destabilizes the respiratory chain complexes and leads to their rapid degradation and low steady state levels. Destabilization could be manifested by a change in the structural properties of the bilayer or of the proteins themselves. Alternatively, the low levels of respiratory components may arise from the failure of the cells to adapt to respiratory conditions and activate the expression of mitochondrial proteins upon the depletion of available glucose. The production of respiratory chain components is normally accelerated in stationary phase cells that we used for our studies (39).2 We have not been able to test whether the failure to recover from catabolite repression is responsible for the low levels of respiratory components because our coq5 mutants do not grow under nonrepressing conditions with galactose as a carbon source. An explanation for this phenomenon awaits further investigations.


FOOTNOTES

*   This research was supported by Medical Research Council of Canada Grant PG-11440 (to B. D. L.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Dagger    K.M.R. was supported by studentships from the Alberta Heritage Foundation for Medical Research and the Medical Research Council of Canada. Present address: Dept. of Biology, 0347, University of California, San Diego, Pacific Hall, Room 2216, 9500 Gilman Dr., La Jolla, CA 92093-0347.
§   To whom correspondence should be addressed: Dept. of Biochemistry, University of Alberta, Edmonton, Alberta T6G 2H7, Canada. Tel.: 403-492-4853; Fax: 403-492-0886; E-mail: lem-1{at}bones.biochem.ualberta.ca.
1   The abbreviations used are: Q, ubiquinone; kb, kilobase pair(s); Tricine, N-[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]glycine.
2   K. M. Robinson and B. D. Lemire, unpublished observations.

ACKNOWLEDGEMENTS

We thank Dr. Catherine Clarke (UCLA, Los Angeles, CA) for yeast strains, Dr. I. G. Young (Canberra, Australia) for the E. coli strain, and Dr. Gottfried Schatz (Basel, Switzerland) for antibodies.


REFERENCES

  1. Daniels, D. L., Plunkett, G., III, Burland, V., and Blattner, F. R. (1992) Science 257, 771-778 [Medline] [Order article via Infotrieve]
  2. Trumpower, B. L. (1990) J. Biol. Chem. 265, 11409-11412 [Free Full Text]
  3. Ernster, L., and Forsmark-Andree, P. (1993) Clin. Invest. 71, S60-S65 [Medline] [Order article via Infotrieve]
  4. Tzagoloff, A., and Dieckmann, C. L. (1990) Microbiol. Rev. 54, 211-225
  5. Gibson, F., and Young, I. G. (1978) Methods Enzymol. 53, 600-609 [Medline] [Order article via Infotrieve]
  6. Wu, G., Williams, H. D., Zamanian, M., Gibson, F., and Poole, R. K. (1992) J. Gen. Microbiol. 138, 2101-2112 [Medline] [Order article via Infotrieve]
  7. Clarke, C. F., Williams, W., and Teruya, J. H. (1991) J. Biol. Chem. 266, 16636-16644 [Abstract/Free Full Text]
  8. Marbois, B. N., and Clarke, C. F. (1996) J. Biol. Chem. 271, 2995-3004 [Abstract/Free Full Text]
  9. Hsu, A. Y., Poon, W. W., Shepherd, J. A., Myles, D. C., and Clarke, C. F. (1996) Biochemistry 35, 9797-9806 [CrossRef][Medline] [Order article via Infotrieve]
  10. Ashby, M. N., and Edwards, P. A. (1990) J. Biol. Chem. 265, 13157-13164 [Abstract/Free Full Text]
  11. Ashby, M. N., Kutsunai, S. Y., Ackermann, S., Tzagoloff, A., and Edwards, P. A. (1992) J. Biol. Chem. 267, 4128-4136 [Abstract/Free Full Text]
  12. Ackrell, B. A. C., Johnson, M. K., Gunsalus, R. P., and Cecchini, G. (1992) in Chemistry and Biochemistry of Flavoenzymes (Müller, F., ed), Vol. III, pp. 229-297, CRC Press, Inc., Boca Raton, FL
  13. Robinson, K. M., von Kieckebusch-Gück, A., and Lemire, B. D. (1991) J. Biol. Chem. 266, 21347-21350 [Abstract/Free Full Text]
  14. de Kok, J., Muller, J. L. M., and Slater, E. C. (1975) Biochim. Biophys. Acta 387, 441-450 [Medline] [Order article via Infotrieve]
  15. Gietz, D., St. Jean, A., Woods, R. A., and Schiestl, R. H. (1992) Nucleic Acids Res. 20, 1425 [Medline] [Order article via Infotrieve]
  16. Young, I. G., McCann, L. M., Stroobant, P., and Gibson, F. (1971) J. Bacteriol. 105, 769-778 [Medline] [Order article via Infotrieve]
  17. Rose, M. D., Novick, P., Thomas, J. H., Botstein, D., and Fink, G. R. (1987) Gene (Amst.) 60, 237-243 [CrossRef][Medline] [Order article via Infotrieve]
  18. Gietz, R. D., and Sugino, A. (1988) Gene (Amst.) 74, 527-534 [CrossRef][Medline] [Order article via Infotrieve]
  19. Jesnowski, R., Naehring, J., and Wolf, K. (1995) Curr. Genet. 27, 318-319 [Medline] [Order article via Infotrieve]
  20. Ellison, M. J., and Hochstrasser, M. (1991) J. Biol. Chem. 266, 21150-21157 [Abstract/Free Full Text]
  21. Yaffe, M. (1991) Methods Enzymol. 194, 627-643 [Medline] [Order article via Infotrieve]
  22. Robinson, K. M., and Lemire, B. D. (1992) J. Biol. Chem. 267, 10101-10107 [Abstract/Free Full Text]
  23. Birnboim, H. C., and Doly, J. (1979) Nucleic Acids Res. 7, 1513-1523 [Abstract]
  24. Dibrov, P. (1993) FEBS Lett. 336, 530-534 [CrossRef][Medline] [Order article via Infotrieve]
  25. Pringle, J. R., Adams, A. E. M., Drubin, D. G., and Haarer, B. K. (1991) Methods Enzymol. 194, 565-602 [Medline] [Order article via Infotrieve]
  26. Crane, F. L., and Barr, R. (1971) Methods Enzymol. 18, 137-165
  27. Bullis, B. L., and Lemire, B. D. (1994) J. Biol. Chem. 269, 6543-6549 [Abstract/Free Full Text]
  28. Mattoon, J. R., Beck, J. C., Carvajal, E., and Malamud, D. R. (1979) Methods Enzymol. 56, 117-131 [Medline] [Order article via Infotrieve]
  29. Beattie, D. S., Japa, S., Howton, M., and Zhu, Q.-S. (1992) Arch. Biochem. Biophys. 292, 499-505 [Medline] [Order article via Infotrieve]
  30. de Santis, A., and Melandri, B. A. (1984) Arch. Biochem. Biophys. 232, 354-365 [Medline] [Order article via Infotrieve]
  31. Tzagoloff, A., Akai, A., and Needleman, R. B. (1975) J. Bacteriol. 122, 826-831 [Medline] [Order article via Infotrieve]
  32. Branda, S. S., and Isaya, G. (1995) J. Biol. Chem. 270, 27366-27373 [Abstract/Free Full Text]
  33. Cox, G. B., and Downie, J. A. (1979) Methods Enzymol. 56, 106-117 [Medline] [Order article via Infotrieve]
  34. Wu, G., Williams, H. D., Gibson, F., and Poole, R. K. (1993) J. Gen. Microbiol. 139, 1795-1805 [Medline] [Order article via Infotrieve]
  35. Lill, R., and Neupert, W. (1996) Trends Cell Biol. 6, 5661
  36. Ingrosso, D., Fowler, A. V., Bleibaum, J., and Clarke, S. (1989) J. Biol. Chem. 264, 20131-20139 [Abstract/Free Full Text]
  37. Bentley, R., and Meganathan, R. (1987) in Escherichia coli and Salmonella typhimurium Cellular and Molecular Biology (Neidhardt, F. C., ed), Vol. I, pp. 512-520, American Society for Microbiology, Washington, D. C.
  38. Attardi, G., and Schatz, G. (1988) Annu. Rev. Cell Biol. 4, 289-333 [CrossRef]
  39. Kim, I.-C., and Beattie, D. S. (1973) Eur. J. Biochem. 36, 509-518 [Medline] [Order article via Infotrieve]
  40. Glick, B. S. (1991) Methods Cell Biol. 34, 389-399 [Medline] [Order article via Infotrieve]

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.